The
global Preimplantation Genetic Testing Market is expected to grow at a CAGR of 10.0%
between 2017 and 2022. Factors driving the growth of this market include the
growing rate of infertility across the world and increasing public-private
investments in the field of preimplantation genetic testing among others.
Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo
Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer,
Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics,
Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene
Corporation (U.S.) are some of the major manufacturers in this market; whereas,
Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix
Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and
Progenesis (U.S.) are some of the major service providers.
View more detailed
TOC @
http://www.marketsandmarkets.com/Market-Reports/preimplantation-genetic-testing-market-605.html
Analysis
of the market developments between 2014 and 2017 (January) show that agreements,
partnerships, and collaborations were the most widely adopted growth strategies
by players in the market. Players adopted these strategies to strengthen their
market position by collaborating to develop and provide technologically
advanced products to its customer base. For instance, in June 2016, the Global
Fertility Alliance pioneered by Genea (Australia), Merck (U.S.), and Illumina
Inc. (U.S.) collaborated with two new members, namely, ZEISS (Germany) and
Hamilton Thorne Ltd. (U.S.) to improve innovation and progress in the field of
fertility treatment. Another strategy adopted by market players are product
launches.
Illumina,
Inc. (U.S.) held the leading position in the global preimplantation genetic testing
market in 2016. The company has been focusing on agreements, partnerships, and
product launches to maintain this position in the market. In 2014, it
introduced VeriSeq PGS, NextSeq 500 System, and HiSeq X Ten in the market,
which enabled it to garner a high share. The company has a strong global
presence with more than 54% of its revenue generated from the U.S. and more than
23% from the European region.
Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsample.asp?id=605
In
2016, Thermo Fisher Scientific Inc. (U.S.) acquired Life Technologies
Corporation, a biotechnology company with more than 50,000 products and
customers in 160 countries, and established a segment called Life Science Solutions.
Through this acquisition, the company entered the highly consolidated
preimplantation genetic diagnosis and screening market. Life Technologies
acquired Ion Torrent in 2010, which added Ion PGM and Proton to its portfolio.
Thermo Fisher Scientific also provides sequencing reagents and consumables
along with services. The company has a strong global presence with a
well-established supply chain that helped it to garner a prominent share in the
preimplantation genetic diagnosis and screening market in 2016. It also aspires
to develop unique next-generation sequencing and bioinformatics platforms for
researchers to support and enhance genetic construction, design, sequencing,
and synthesis.
No comments:
Post a Comment